COR-101 is under clinical development by CORAT Therapeutics and currently in Phase II for Coronavirus Disease 2019 (COVID-19). According to GlobalData, Phase II drugs for Coronavirus Disease 2019 (COVID-19) have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how COR-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
COR-101 overview
COR-101 is under development for the treatment of coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It is administered through intravenous route. It acts by targeting spike (S1) protein of SARS-CoV-2 virus.
CORAT Therapeutics overview
CORAT Therapeutics (CORAT) is a biopharmaceutical company that focuses on the development of therapeutic drugs composed of novel fully human neutralizing antibodies against COVID-19. The company’s lead product, COR-101, is designed to bind to the viral receptor binding domain (RBD) region and block the attachment of the virus to human cells. The company is also developing products such as COR-201 and COR-311. The company’s products can also be used for prophylaxis, CORAT Therapeutics is headquartered in Braunschweig, Lower Saxony, Germany.
For a complete picture of COR-101’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
